These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 38082288)

  • 1. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
    Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
    Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus.
    Zhao L; Meng J; Bai X; Zhang D; Yang X; Yang Y; Cai G; Liu X
    Eur J Med Res; 2024 Jul; 29(1):363. PubMed ID: 38997754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Gong Y; Bai X; Zhang D; Yang X; Qin Z; Yang Y; Zhou Y; Meng J; Liu X
    Lipids Health Dis; 2024 May; 23(1):157. PubMed ID: 38796440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Jin Y; Zhao H; Hou Y; Song G
    Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.
    Rizzo MR; Barbieri M; Boccardi V; Angellotti E; Marfella R; Paolisso G
    J Gerontol A Biol Sci Med Sci; 2014 Sep; 69(9):1122-31. PubMed ID: 24671867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
    Chang CH; Lu CH; Chung CH; Su SC; Kuo FC; Liu JS; Li PF; Huang CL; Chen KC; Ho LJ; Kuo CC; Chang CY; Lin MS; Liu YC; Chu NF; Lee CH; Hung YJ; Hsieh PS; Lin FH; Hsieh CH; Chien WC
    J Chin Med Assoc; 2022 Jul; 85(7):747-753. PubMed ID: 35648138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
    Liu X; Men P; Wang B; Cai G; Zhao Z
    Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus.
    Choi Y; Ko SH; Chang K; Yoo KD; Ihm SH
    J Diabetes; 2023 Nov; 15(11):944-954. PubMed ID: 37528628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake.
    Okada S; Okada K; Okada J; Kikkawa K; Yamada E; Saito T; Andou T; Ohshima K
    Diabetes Metab Syndr; 2023 Jul; 17(7):102806. PubMed ID: 37343509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.
    Bouzas C; Pastor R; Garcia S; Monserrat-Mesquida M; Martínez-González MÁ; Salas-Salvadó J; Corella D; Goday A; Martínez JA; Alonso-Gómez ÁM; Fernández-Barceló O; Vioque J; Romaguera D; Lopez-Miranda J; Estruch R; Tinahones FJ; Lapetra J; Serra-Majem L; Riquelme-Gallego B; Martín-Sánchez V; Pintó X; Delgado-Rodriguez M; Matía P; Vidal J; Cardenas-Salas JJ; Daimiel L; Ros E; Toledo E; Manzanares JM; Gonzalez-Monge I; Muñoz MÁ; Martinez-Urbistondo D; Tojal-Sierra L; Muñoz-Bravo C; Miralles-Gisbert S; Martin M; García-Ríos A; Castro-Barquero S; Fernández-García JC; Santos-Lozano JM; Basterra-Gortari FJ; Gutiérrez-Carrasquilla L; Guillem-Saiz P; Satorres A; Abete I; Sorto-Sanchez C; Díez-Espino J; Babio N; Fitó M; Tur JA
    Biomed Pharmacother; 2023 May; 161():114561. PubMed ID: 36934556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus.
    Li J; Liu Y; Hao P
    Diabetes Res Clin Pract; 2023 Aug; 202():110798. PubMed ID: 37356725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
    Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
    Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer.
    Saito A; Kitayama J; Horie H; Koinuma K; Kawashima R; Ohzawa H; Yamaguchi H; Kawahira H; Mimura T; Lefor AK; Sata N
    Cancer Res Commun; 2021 Nov; 1(2):106-114. PubMed ID: 36860286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review.
    Ruan Z; Zou H; Lei Q; Ung COL; Shi H; Hu H
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):555-574. PubMed ID: 35152812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
    Front Immunol; 2022; 13():843480. PubMed ID: 35309321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
    Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
    BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping.
    Du Z; Lu T; Gao M; Tian L
    Acta Diabetol; 2022 Dec; 59(12):1539-1549. PubMed ID: 36002590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus.
    Wei X; Bai Y; Wang Z; Zheng X; Jin Z; Liu X
    Diabetol Metab Syndr; 2021 Aug; 13(1):88. PubMed ID: 34446063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis.
    Huang L; Zhong W; Liang X; Wang H; Fu SE; Luo Z
    J Clin Densitom; 2024; 27(1):101455. PubMed ID: 38101289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.